Company profile for Forge Therapeutics, Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Forge Therapeutics is a biotechnology company developing novel medicines by combining bioinorganic with medicinal chemistry to target metalloenzymes. Metalloenzymes make up over 30% of all known enzymes in nature and are critically important for a wide range of biochemical processes and biological catalysis. Forge has developed a fundamentally new approach for the discovery of metalloenzyme inhibitors by focusing first on the ...
Forge Therapeutics is a biotechnology company developing novel medicines by combining bioinorganic with medicinal chemistry to target metalloenzymes. Metalloenzymes make up over 30% of all known enzymes in nature and are critically important for a wide range of biochemical processes and biological catalysis. Forge has developed a fundamentally new approach for the discovery of metalloenzyme inhibitors by focusing first on the metal in the enzyme active site. Forge was founded based on work that emerged over the last 15 years from the laboratory of Professor Seth Cohen at the University of California San Diego.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
10578 Science Center Drive Suite 205 San Diego, CA 92121
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/blacksmith-medicines-announces-merger-with-forge-therapeutics-to-create-leading-company-developing-medicines-targeting-metalloenzymes-301711871.html#:~:text=(Blacksmith)%2C%20and%20Forge%20Therapeutics,proteins%20called%20metalloenzymes%2C%20with%20initial

PR NEWSWIRE
03 Jan 2023

https://www.raps.org/news-and-articles/news-articles/2019/6/fda-plots-shift-away-from-csr-pilot-to-forge-new-t

Zachary Brennan RAPS
27 Jun 2019

http://www.pharmabiz.com/NewsDetails.aspx?aid=115435&sid=2

PHARMABIZ
26 Apr 2019

https://www.prnewswire.com/news-releases/forge-and-basilea-enter-into-multi-target-agreement-to-discover-and-develop-novel-antibiotics-300837535.html

PR NEWSWIRE
24 Apr 2019
Forge Therapeutics Achieves CARB-X Milestone
Forge Therapeutics Achieves CARB-X Milestone

01 Aug 2018

// CONTRACT PHARMA

https://www.contractpharma.com/contents/view_breaking-news/2018-08-01/forge-therapeutics-achieves-carb-x-milestone/9778

CONTRACT PHARMA
01 Aug 2018

http://cen.acs.org/articles/95/i18/Forge-Therapeutics-scores-15-million.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+biological_scene+%28Chemical+%26+Engineering+News%3A+Biological+SCENE%29

Lisa M. Jarvis CEN
29 Apr 2017

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty